{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:49:58Z","timestamp":1753890598415,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> There were few data about the clinical profiles and long-term outcomes in Chinese patients with atrial fibrillation (AF) and bioprosthetic valves.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The retrospective study enrolled 903 patients with bioprosthetic valve replacement at our hospital and discharged with a diagnosis of AF from January 2010 to December 2018.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median age was 65.6 (61.9\u201369.1) years, and 548 (60.7%) patients were women. During a follow-up period of 3.84 (2.64\u20135.51) years, 68 (1.8 per 100 person-years) patients died, 81 (2.1 per 100 person-years) patients developed thromboembolism, and 23 (0.6 per 100 person-years) patients experienced major bleeding. The CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score, as a categorical variable (low, moderate, or high risk), predicted the risk of thromboembolism with the C-statistic of 0.6 (95% CI: 0.511\u20130.689, <jats:italic>p<\/jats:italic> = 0.046). The incidence of the CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score increment was 11.6 per 100 person-years, and the annual reclassification rate of stroke risk (from a low or moderate group to a higher group) was 12.7%. The current proportion of oral anticoagulants was 52.3, 59, and 63.2%, respectively, in the low, moderate, and high stroke risk groups. Age (OR: 1.04, 95% CI: 1.01\u20131.06, <jats:italic>p<\/jats:italic> = 0.01), left atrial size (OR: 1.05, 95% CI: 1.03\u20131.08, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), and rheumatic heart disease (OR: 1.49, 95% CI: 1.05\u20132.10, <jats:italic>p<\/jats:italic> = 0.025) were positively associated with the use of oral anticoagulants. The history of chronic kidney disease (OR: 0.20, 95% CI: 0.05\u20130.76, <jats:italic>p<\/jats:italic> = 0.018), prior surgical ablation (OR: 0.33, 95% CI: 0.24\u20130.47, <jats:italic>p<\/jats:italic> &amp;lt; 0.001), and antiplatelet agent use (OR: 0.08, 95% CI: 0.05\u20130.13, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) were inversely related to the use of oral anticoagulants. Higher admission estimated glomerular filtration rate (HR: 0.515, 95% CI: 0.311\u20130.853, <jats:italic>p<\/jats:italic> = 0.01), left ventricular ejection fraction (HR: 0.961, 95% CI: 0.931\u20130.992, <jats:italic>p<\/jats:italic> = 0.014), concomitant surgical ablation (HR: 0.348, 95% CI: 0.171\u20130.711, <jats:italic>p<\/jats:italic> = 0.004), and rheumatic heart disease history (HR: 0.515, 95% CI: 0.311\u20130.853, <jats:italic>p<\/jats:italic> = 0.01) were associated with a lower risk of death. Surgical ablation (HR: 0.263, 95% CI: 0.133\u20130.519, <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and oral anticoagulants (HR: 0.587, 95% CI: 0.375\u20130.918, <jats:italic>p<\/jats:italic> = 0.019) were related to a lower risk of thromboembolism.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Chinese patients with AF and bioprosthetic valve(s) were relatively young and had a high prevalence of rheumatic heart disease with few comorbidities. The percentage of mitral bioprosthetic valve replacement was high. The proportion of concomitant surgical ablation or surgical left atrial appendage occlusion or exclusion was relatively low. The thromboembolic events were the major long-term adverse events. The anticoagulation therapy was underused in patients at moderate or high stroke risk. The CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc score was verified to be used for predicting stroke risk in this population. The stroke risk dynamically changed; it needed to be reestimated once the risk factor changed.<\/jats:p>","DOI":"10.3389\/fcvm.2021.665124","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T04:46:44Z","timestamp":1623300404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The Characteristics, Long-Term Outcomes, Risk Factors, and Antithrombotic Therapy in Chinese Patients With Atrial Fibrillation and Bioprosthetic Valves"],"prefix":"10.3389","volume":"8","author":[{"given":"Jiameng","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinghui","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","author":"Nkomo","year":"2006","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ijcard.2005.03.048","article-title":"Prevalence of chronic rheumatic heart disease in Chinese adults","volume":"107","author":"Zhimin","year":"2006","journal-title":"Int J Cardiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ijcard.2016.11.301","article-title":"A hospital-based survey of patients with severe valvular heart disease in China","volume":"231","author":"Hu","year":"2017","journal-title":"Int J Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ijcard.2004.12.042","article-title":"Retrospective investigation of hospitalised patients with atrial fibrillation in mainland China","volume":"105","year":"2005","journal-title":"Int J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cvdpc.2008.09.001","article-title":"Management of atrial fibrillation in Chinese patients","volume":"4","author":"Ma","year":"2009","journal-title":"CVD Prev Cont."},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jjcc.2020.02.006","article-title":"Registry of antithrombotic therapy in atrial fibrillation patients with bioprosthetic valves: a retrospective observational study","volume":"76","author":"Izumi","year":"2020","journal-title":"J Cardiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s10557-020-07038-1","article-title":"Rationale, design, and baseline characteristics of the bioprosthetic valves with atrial fibrillation (BPV-AF) study","volume":"34","author":"Furukawa","year":"2020","journal-title":"Cardiovasc Drugs Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.clinthera.2019.10.008","article-title":"Clinical benefit of direct oral anticoagulants versus vitamin k antagonists in patients with atrial fibrillation and bioprosthetic heart valves","volume":"41","author":"Russo","year":"2019","journal-title":"Clin Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1136\/heartjnl-2019-314767","article-title":"Oral anticoagulants in atrial fibrillation with valvular heart disease and bioprosthetic heart valves","volume":"105","author":"Malik","year":"2019","journal-title":"Heart."},{"key":"B10","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/clc.23178","article-title":"Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial","volume":"42","author":"Guimaraes","year":"2019","journal-title":"Clin Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1055\/s-0037-1615261","article-title":"Antagonist oral anticoagulants use in patients with atrial fibrillation and bioprosthetic heart valves\/prior surgical valve repair: a multicenter clinical practice experience","volume":"44","author":"Russo","year":"2018","journal-title":"Semin Thromb Hemost."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1161\/CIRCULATIONAHA.116.026714","article-title":"Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves","volume":"135","author":"Carnicelli","year":"2017","journal-title":"Circulation."},{"key":"B13","doi-asserted-by":"publisher","first-page":"f93","DOI":"10.1093\/ehjcvp\/pvaa011","article-title":"All-cause mortality, stroke, and bleeding in patients with atrial fibrillation and valvular heart disease","volume":"7","author":"Strange","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e13589","DOI":"10.1111\/ijcp.13589","article-title":"Thromboembolic and bleeding outcomes in patients with atrial fibrillation and valvular heart disease: a descriptive nationwide cohort study","volume":"74","author":"Melgaard","year":"2020","journal-title":"Int J Clin Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1253\/circj.CJ-19-1158","article-title":"Impact of valvular heart disease on mortality, thromboembolic and cardiac events in japanese patients with atrial fibrillation - the fushimi AF registry","volume":"84","author":"Doi","year":"2020","journal-title":"Circ J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.3390\/jcm8101624","article-title":"Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"8","author":"Moon","year":"2019","journal-title":"J Clin Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.kint.2018.10.019","article-title":"Development and validation of a more accurate estimating equation for glomerular filtration rate in a Chinese population","volume":"95","author":"Li","year":"2019","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest."},{"key":"B19","unstructured":"FuwaiC\n            HospitalC\n          National Center For Cardiovascular Diseases, Cardiovascular Surgery Outcomes 20192020"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1160\/TH16-01-0007","article-title":"Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. The Loire Valley Atrial Fibrillation Project","volume":"115","author":"Philippart","year":"2016","journal-title":"Thromb Haemost."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1055\/s-0039-1683933","article-title":"Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (Males) or 1 (Females): implications for reassessment of stroke risk in initially 'low-risk' patients","volume":"119","author":"Chao","year":"2019","journal-title":"Thromb Haemost."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1055\/s-0038-1651482","article-title":"Dynamic changes of CHA2DS2-VASc score and the risk of ischaemic stroke in asian patients with atrial fibrillation: a nationwide cohort study","volume":"118","author":"Yoon","year":"2018","journal-title":"Thromb Haemost."},{"key":"B23","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/heartjnl-2016-309630","article-title":"Anticoagulation versus antiplatelet or no therapy in patients undergoing bioprosthetic valve implantation: a systematic review and meta-analysis","volume":"103","author":"Masri","year":"2017","journal-title":"Heart."},{"key":"B24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2012.05.029","article-title":"Early anticoagulation of bioprosthetic aortic valves in older patients: results from the society of thoracic surgeons adult cardiac surgery national database","volume":"60","author":"Brennan","year":"2012","journal-title":"J Am Coll Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1097\/CM9.0000000000001151","article-title":"Contemporary characteristics, management, and outcomes of patients hospitalized for atrial fibrillation in China: results from the real-world study of Chinese atrial fibrillation registry","volume":"133","author":"Zhao","year":"2020","journal-title":"Chin Med J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.amjcard.2021.01.016","article-title":"Comparison of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and bioprosthetic heart valves","volume":"146","author":"Duan","year":"2021","journal-title":"Am J Cardiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12872-016-0308-1","article-title":"Rationale and design of the chinese atrial fibrillation registry study","volume":"16","author":"Du","year":"2016","journal-title":"BMC Cardiovasc Disord."},{"key":"B28","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.12659\/MSM.917131","article-title":"Control of anticoagulation therapy in patients with atrial fibrillation treated with warfarin: a study from the Chinese atrial fibrillation registry","volume":"25","author":"Liang","year":"2019","journal-title":"Med Sci Monit."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3390\/jcm9051345","article-title":"Long-term survival following surgical ablation for atrial fibrillation concomitant to isolated and combined coronary artery bypass surgery-analysis from the polish national registry of cardiac surgery procedures (KROK)","volume":"9","author":"Kowalewski","year":"2020","journal-title":"J Clin Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jtcvs.2019.07.131","article-title":"Surgical ablation of atrial fibrillation concomitant to coronary-artery bypass grafting provides cost-effective mortality reduction","volume":"160","author":"Rankin","year":"2020","journal-title":"J Thor Cardiov Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/ejcts\/ezz298","article-title":"Surgical ablation for atrial fibrillation during isolated coronary artery bypass surgery","volume":"57","author":"Suwalski","year":"2020","journal-title":"Eur J Cardiothorac Surg."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/europace\/eux336","article-title":"Surgical ablation of atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"20","author":"McClure","year":"2018","journal-title":"Europace."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/j.jtcvs.2019.10.159","article-title":"Ablation of atrial fibrillation during coronary artery bypass grafting: late outcomes in a medicare population","volume":"161","author":"Malaisrie","year":"2019","journal-title":"J Thor Cardiov Surg"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.hrthm.2019.05.001","article-title":"Five-year outcomes in cardiac surgery patients with atrial fibrillation undergoing concomitant surgical ablation versus no ablation. The long-term follow-up of the PRAGUE-12 Study","volume":"16","author":"Osmancik","year":"2019","journal-title":"Heart Rhythm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/j.jtcvs.2018.09.023","article-title":"Concomitant ablation of atrial fibrillation in rheumatic mitral valve surgery","volume":"157","author":"Kim","year":"2019","journal-title":"J Thorac Cardiovasc Surg."},{"key":"B36","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/europace\/euaa235","article-title":"Atrial fibrillation and the risk of ischaemic strokes or intracranial haemorrhages: comparisons of the catheter ablation, medical therapy, and non-atrial fibrillation population","volume":"23","author":"Kim","year":"2020","journal-title":"Europace."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N Engl J Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/ejcts\/ezu291","article-title":"Surgical left atrial appendage occlusion during cardiac surgery for patients with atrial fibrillation: a meta-analysis","volume":"47","author":"Tsai","year":"2015","journal-title":"Eur J Cardiothorac Surg."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cjca.2013.06.015","article-title":"Left atrial appendage occlusion study II (LAAOS II)","volume":"29","author":"Whitlock","year":"2013","journal-title":"Can J Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ahj.2004.09.054","article-title":"Left atrial appendage occlusion study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke","volume":"150","author":"Healey","year":"2005","journal-title":"Am Heart J."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.665124\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T04:46:52Z","timestamp":1623300412000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2021.665124\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":40,"alternative-id":["10.3389\/fcvm.2021.665124"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2021.665124","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"article-number":"665124"}}